No Result
View All Result
Success American Investors
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Success American Investors
No Result
View All Result
Home Investing

Weight-loss drug firm becomes Europe’s most valuable

by
September 6, 2023
in Investing
0
Weight-loss drug firm becomes Europe’s most valuable
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

The maker of weight-loss drug Wegovy has become Europe’s most valuable firm, dethroning the French luxury conglomerate LVMH.

Shares rose after the Danish pharmaceutical giant, Novo Nordisk, launched the popular drug in the UK.

At the close of trading on Monday, the firm had a stock market valuation of $428bn (£339bn).

The drug is now available on the National Health Service in the UK and also on the private market.

Wegovy is an obesity treatment that is taken once a week which tricks people into thinking that they are already full, so they end up eating less and losing weight.

Famous personalities such as Elon Musk are among the reported users of the drug, which has captivated Hollywood and the public more widely since it was approved by regulators in the US in 2021.

Wegovy and Ozempic – a diabetes treatment with similar effects – have been described as “miracle” drugs.

But experts warn the jabs are not a quick fix nor a substitute for a healthy diet and exercise.

In trials, users often put weight back on after stopping treatment.

There has been a global shortage of the jabs so only limited stock arrived for the NHS in the UK on Monday.

The company said it would continue to restrict global supplies as it works to ramp up manufacturing.

Sophie Lund-Yates, lead equity analyst at Hargreaves Lansdown, said that the firm had been “genuinely surprised” by the uptake and said it had been “a victim of its own success”.

“It’s not common that you see a pharmaceutical company so entrenched in popular culture but there are people saying that we need to take a step back and ensure it is being used appropriately and responsibly. Of course, with a lot of fanfare for a drug, you are risking a lot of blowback in the future,” she said.

In the UK, NHS guidelines say patients can only access Wegovy, which contains the drug semaglutide, if they are significantly overweight and have weight-related health problems.

According to the Organisation for Economic Co-operation and Development (OECD), nearly one in three adults are obese in the UK, which is the highest level in Europe.

Last month, a new trial showed Wegovy has also been proven to reduce the risk of a stroke or heart attack.

While the findings still have to be fully reviewed, experts agreed the results were potentially significant.

Read more:
Weight-loss drug firm becomes Europe’s most valuable

Previous Post

Government proposes changes to disability and illness benefits

Next Post

Britain’s school concrete crisis could cost over £150M

Next Post
Britain’s school concrete crisis could cost over £150M

Britain’s school concrete crisis could cost over £150M

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest
Vertica: The new Israeli start-up challenger to Viagra proving ‘life-changing’ for men with ED

Vertica: The new Israeli start-up challenger to Viagra proving ‘life-changing’ for men with ED

February 14, 2024

Last Day to Give in 2023!

December 31, 2023
Idaho Bucks Managed Care Trend

Idaho Bucks Managed Care Trend

December 5, 2023

The Producer Price Index

September 9, 2023

The Southern Cause: What Led to Secession

0

0

0

0

The Southern Cause: What Led to Secession

May 31, 2025

“Our Marx”: The Great Herbert Spencer

May 31, 2025
UK steel industry faces fresh crisis as US tariff jumps to 50%

UK steel industry faces fresh crisis as US tariff jumps to 50%

May 31, 2025

Global Outcry Against U.S. Prison Forced Labor Grows as Demands for Change Mount

May 31, 2025

Recent News

The Southern Cause: What Led to Secession

May 31, 2025

“Our Marx”: The Great Herbert Spencer

May 31, 2025
UK steel industry faces fresh crisis as US tariff jumps to 50%

UK steel industry faces fresh crisis as US tariff jumps to 50%

May 31, 2025

Global Outcry Against U.S. Prison Forced Labor Grows as Demands for Change Mount

May 31, 2025

Disclaimer: SuccessAmericanInvestors.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 SuccessAmericanInvestors. All Rights Reserved.

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2025 SuccessAmericanInvestors. All Rights Reserved.